Koya Medical Eyes Growth with Investor Showcase for Vascular Tech

DALLAS, TX – May 26, 2026 – Dallas-based medtech innovator Koya Medical is preparing for a pivotal week, announcing its leadership will meet with the investment community at two high-profile conferences in early June. The move signals a strategic push to accelerate the growth of its patient-centered solutions for vascular diseases, a field affecting over 35 million Americans.

CEO Andy Doraiswamy and CFO Damian Rippole are scheduled for private meetings at the 2026 Jefferies Global Healthcare Conference in New York on June 2, followed by William Blair's 46th Annual Growth Stock Conference in Chicago on June 3. At the center of their pitch will be the commercial momentum for the company's portfolio—including its Dayspring® non-pneumatic compression treatment for chronic edema—and sharing progress on its vascular pipeline and ongoing clinical research.

A Strategic Pitch to Wall Street

For Koya Medical, these conferences represent more than just a calendar entry; they are a critical opportunity to secure the capital needed to scale its operations and expand its market reach. Founded in 2018, the company has successfully navigated the challenging early stages of medtech development, attracting significant investor interest along the way.

To date, Koya has raised $37 million through multiple funding rounds, including a crucial $26 million Series B round in 2022. The company's potential has attracted a roster of prominent healthcare-focused investors, such as Arboretum Ventures, 3x5 Partners, and Asahi Kasei Ventures. More recently, in November 2023, Koya secured $30 million in financing led by OrbiMed, a leading healthcare investment firm, to specifically support the strategic growth of Dayspring. This sustained financial backing has fueled the company's progress, leading to a valuation of $176.1 million as of September 2025 and an estimated annual revenue of $58.7 million last year. Now, with a proven product and growing revenue, Doraiswamy and Rippole will aim to convince investors that Koya is poised for its next major growth phase.

Redefining Treatment with Patient Mobility

The foundation of Koya's investor pitch and its market potential lies in the Dayspring system, an FDA-cleared device designed to treat lymphedema, chronic venous insufficiency, and related conditions. These ailments, which cause painful swelling and can severely limit mobility, affect an estimated 5 to 10 million people in the U.S. alone, often as a debilitating side effect of cancer treatment or due to underlying venous disease.

Traditionally, treatment has relied on advanced pneumatic compression devices (APCDs), which use air-filled garments to squeeze fluid from the limbs. While effective, these systems typically require patients to remain stationary and tethered to a machine for hours at a time—a major barrier to adherence and quality of life.

Koya Medical's Dayspring disrupts this paradigm. It is a wearable, non-pneumatic system that utilizes patented Flexframe technology within limb-specific garments to deliver active, sequential compression. Controlled by a small, programmable unit and an accompanying mobile app, the system is designed to be worn while patients go about their daily activities. This core innovation—enabling movement during therapy—not only improves convenience but is designed to work with the body's natural muscle pump to enhance lymphatic drainage, representing a fundamental shift from passive, immobilizing treatments.

The Clinical Proof Behind the Promise

Koya Medical is backing its claims of superiority with robust clinical data. The company has completed multiple head-to-head trials comparing Dayspring to traditional APCDs, with results published in peer-reviewed journals.

The landmark TEAYS study, a multicenter, randomized trial published in the Journal of Vascular Surgery, provided compelling evidence. In the study, patients with lower extremity lymphedema using Dayspring experienced a mean limb volume reduction of 369.9 mL, a figure significantly greater than the 83.1 mL reduction seen in patients using APCDs.

Beyond physical outcomes, the study highlighted a dramatic difference in patient experience. Adherence to the prescribed therapy was significantly higher with Dayspring (81%) compared to APCDs (56%). Furthermore, 78% of patients stated they preferred the Koya device, citing the freedom to move and engage in daily life. Quality of life scores also showed statistically significant improvements for the Dayspring group across symptoms, appearance, and function. Similar positive results were observed in the NILE study, which focused on breast cancer-related lymphedema and found adherence rates of 95.6% for Dayspring versus 49.8% for APCDs.

Navigating the Path to Market

The journey from a promising idea to a market-ready product with strong clinical backing has been a deliberate one for Koya Medical. The company's origin is deeply personal, inspired by founder Andy Doraiswamy's experience watching a family member struggle with lymphedema. This personal connection to the problem has fueled a mission to close treatment gaps and prioritize patient quality of life.

After its founding in 2018, the company operated from Oakland, California, before relocating its headquarters to Dallas in June 2025, a move intended to support its strategic growth and commercial expansion. While Koya has successfully carved out a niche by differentiating Dayspring from competitors like Tactile Medical and Bio Compression Systems, the path forward is not without challenges.

Despite positive clinical data and FDA clearance, securing broad insurance reimbursement remains a key hurdle. While Koya achieved a significant milestone by securing billing codes from the Centers for Medicare & Medicaid Services (CMS) in 2021, some private health plans still classify the technology as "investigative and unproven," withholding coverage and limiting patient access. Overcoming this will be critical for widespread adoption. Additionally, while many patient testimonials are overwhelmingly positive, some online user discussions reflect mixed experiences, with a minority of users feeling underwhelmed by the device's compression compared to traditional pneumatic systems.

Leadership with a Vision

Guiding Koya Medical through these opportunities and challenges is a leadership team with deep experience in medical technology and finance. CEO Andy Doraiswamy holds a Ph.D. in biomedical engineering and has a track record of developing world-changing medical devices, including sight-restoring implants that have treated millions. His previous venture, Oculeve, was successfully acquired by Allergan, demonstrating his ability to guide an innovation from concept to commercial success.

He is complemented by CFO Damian Rippole, a veteran financial executive with over 20 years of experience in the medtech sector. Rippole previously served as CFO at Ebb Therapeutics and played a key financial leadership role at Respironics during its $5 billion acquisition by Philips. His expertise in financial strategy and operations within both private and public medical device companies provides the fiscal discipline necessary to steer Koya's ambitious growth plans. As they head to New York and Chicago, this team will leverage their combined experience to articulate a vision for a company that is not just selling a device, but aiming to set a new standard of care for millions.